An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing

Genetics in Medicine

Volumn 17, Issue 10, 2015, Pages 807-814

  Jung, Jae Woo ^a,b   Kim, Dong Ki ^a   Park, Heung Woo ^a   Oh, Kook Hwan ^a   Joo, Kwon Wook ^a   Kim, Yon Su ^a   Ahn, Curie ^a   Lee, Kyung Wha ^c   Cho, Sang Heon ^a   Min, Kyung Up ^a   Kang, Hye Ryun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

allopurinol; drug hypersensitivity; HLA B 58:01 antigen; immune tolerance; renal insufficiency, chronic

Indexed keywords

ALLOPURINOL; CREATININE; HLA B ANTIGEN; URIC ACID; HISTOCOMPATIBILITY ANTIGEN;

ADULT; ARTICLE; BODY SURFACE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FEMALE; HIGH RISK PATIENT; HLA TYPING; HUMAN; HYPERURICEMIA; INCIDENCE; LEUKOCYTOSIS; LIVER CELL DAMAGE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRURITUS; RENAL CLEARANCE; RETROSPECTIVE STUDY; SEVERE CUTANEOUS ADVERSE REACTION; SKIN DISEASE; TELEPHONE INTERVIEW; URTICARIA; AGED; ALLELE; DESENSITIZATION; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; RISK FACTOR;

ADULT; AGED; ALLELES; ALLOPURINOL; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HISTOCOMPATIBILITY TESTING; HLA-B ANTIGENS; HUMANS; IMMUNE TOLERANCE; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84934946645     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.195     Document Type: Article

References (34)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285
2. Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA 2014; 311: 2231-2232
3. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44
4. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-286
5. Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med 1998; 52: 107-110
6. Hung SI, Chung WH, Liou LB, et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139
7. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J (Clin Res Ed) 1985; 290: 1969-1970
8. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87
9. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486
10. Amstutz U, Shear NH, Rieder MJ, et al.; CPNDS clinical recommendation group. Recommendations for HLA-B15: 02 and HLA-A31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55: 496-506
11. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-Transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732
12. Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013; 56: 119-124
13. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-709
14. Kang HR, Jee YK, Kim YS, et al.; Adverse Drug Reaction Research Group in Korea. Positive and negative associations of HLA class I alleles with allopurinolinduced SCARs in Koreans. Pharmacogenet Genomics 2011; 21: 303-307
15. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 3567-3572
16. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006; 6: 271-277
17. Miller SA, Dykes DD, Polesky HF A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
18. Prasad VK, Yang SY. Allele assignment for HLA-A,-B, and-C genes to the Tenth International Histocompatibility Workshop cell lines. Tissue Antigens 1996; 47: 538-546
19. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A,-B,-C,-DRB1, and-DQB1 genes in the Korean population. Tissue Antigens 2005; 65: 437-447
20. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56
21. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231-238
22. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S
23. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374-389
24. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259
25. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-316
26. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728-733
27. Chen P, Lin JJ, Lu CS, et al.; Taiwan SJS Consortium. Carbamazepineinduced toxic effects and HLA-B1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-1133
28. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813-818
29. Mallal S, Phillips E, Carosi G, et al.; PREDICT-1 Study Team. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579
30. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-Allergic patient. Curr Rheumatol Rep 2001; 3: 29-35
31. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529-2536
32. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013; 43: 1246-1255
33. Zhang W, Doherty M, Bardin T, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324
34. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461